BridgeBio Pharma (BBIO) Receivables (2021 - 2026)

BridgeBio Pharma (BBIO) has 6 years of Receivables data on file, last reported at $205.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 78.05% year-over-year to $205.2 million; the trailing twelve-month figure through Mar 2026 stood at $205.2 million (up 78.05% YoY), and the FY2025 full-year result was $139.4 million, up 2853.07% from the prior year.
• Receivables grew to $205.2 million in Q1 2026, from $139.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $335.9 million in Q1 2024 to a low of $678000.0 in Q3 2024.
• A 5-year average of $68.7 million and a median of $22.8 million in 2022 frame the typical range for Receivables.
• Across the five-year window, Receivables tumbled 94.31% in 2024 and soared 17085.55% in 2025, its largest moves.
• Tracing BBIO's Receivables over 5 years: stood at $33.9 million in 2022, then plunged by 92.18% to $2.7 million in 2023, then soared by 78.12% to $4.7 million in 2024, then jumped by 2853.07% to $139.4 million in 2025, then jumped by 47.17% to $205.2 million in 2026.
• Business Quant data shows BBIO's Receivables at $205.2 million in Q1 2026, $139.4 million in Q4 2025, and $116.5 million in Q3 2025.